OTCMKTS:CXRXF ADVANZ PHARMA (CXRXF) Stock Price, News & Analysis → Read this before you buy AI stocks (From InvestorPlace) (Ad) Free CXRXF Stock Alerts $17.06 0.00 (0.00%) (As of 06/10/2021) Add Compare Share Share Today's Range$17.06▼$17.0650-Day Range$17.06▼$17.0652-Week Range$2.13▼$18.00Volume39 shsAverage Volume11,851 shsMarket Capitalization$834.46 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get ADVANZ PHARMA alerts: Email Address Ad True Market InsidersExposed: 10 CENT Crypto to Explode May 20th?Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 different coins that have returned over 100%... Today, he is now making the biggest crypto call of his ENTIRE career…Click For My #1 FREE Crypto for 2024 About ADVANZ PHARMA Stock (OTCMKTS:CXRXF)ADVANZ PHARMA Corp. Limited, a pharmaceutical company, through its subsidiaries, owns or licenses a portfolio of branded and generic prescription products worldwide. The company operates through two segments: ADVANZ PHARMA International and ADVANZ PHARMA North America. Its ADVANZ PHARMA International segment offers a portfolio of branded and generic prescription products to wholesalers, distributors, hospitals, and pharmacies. This segment's products include Brinavess for the conversion of onset atrial fibrillation to sinus rhythm in adults; Aggrastat, a reversible GP IIb/IIIa inhibitor indicated for use in patients with acute coronary syndrome; Xydalba, a semi-synthetic lipoglycopeptide for the treatment of acute bacterial skin and skin structure infections in adults; and Zevtera/Mabelio, a cephalosporin antibiotic for the treatment of community-acquired and hospital-acquired pneumonia. The company's ADVANZ PHARMA North America segment provides Donnatal for the treatment of irritable bowel syndrome; Zonegran for the treatment of partial seizures in adults with epilepsy; Nilandron for the treatment of metastatic prostate cancer; Lanoxin for the treatment of mild to moderate heart failure and atrial fibrillation; Plaquenil for the treatment of lupus and rheumatoid arthritis; and Photofrin for the treatment of certain types of cancer. It also offers Prostaglandin E1 formulations for the treatment of erectile dysfunction and peripheral arterial occlusive disease under the Prostavasin, Viridal, Vasaprostan, and Edex brands, as well as holds licensed commercialization rights to a pre-registration drug/device combination product, Trevyent for the treatment of pulmonary arterial hypertension. It sells its products through direct sales and local distribution relationships. The company was formerly known as ADVANZ PHARMA Corp. and changed its name to ADVANZ PHARMA Corp. Limited in December 2019. ADVANZ PHARMA Corp. Limited is headquartered in London, the United Kingdom.Read More CXRXF Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CXRXF Stock News HeadlinesApril 7, 2024 | seekingalpha.comPHAT Phathom Pharmaceuticals, Inc.March 12, 2024 | msn.comDimerix completes ‘highly strategic’ $20m cap raise to advance ACTION3 Phase 3 trialFebruary 28, 2024 | msn.comInterim results for Dimerix’s Phase 3 trial of DXB-200 for FSGS kidney disease on track for release in March 2024November 7, 2023 | msn.comDimerix receives $10.7 million upfront payment from Advanz PharmaJanuary 4, 2023 | msn.comApplied Therapeutics adds 19% on partnership with Advanz Pharma for lead assetSeptember 27, 2022 | dallasnews.comMADE in America Act is critical for the pharmaceutical industryAugust 5, 2022 | seekingalpha.comPolyPid to get $2.6M upfront under license deal with Advanz for D-PLEX in EuropeJuly 1, 2022 | benzinga.comIntercept Announces Closing of Transaction with Advanz Pharma to Transfer Rights to Commercialize Ocaliva® for PBC Outside the U.S.May 5, 2022 | seekingalpha.comIntercept Pharma to sell ex-U.S. rights for Ocaliva to Advanz PharmaSee More Headlines Receive CXRXF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ADVANZ PHARMA and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolOTCMKTS:CXRXF CUSIPN/A CIKN/A Webwww.advanzpharma.com Phone44-20-8588-9100FaxN/AEmployees429Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-74,860,000.00 Net Margins-15.31% Pretax MarginN/A Return on EquityN/A Return on Assets-4.38% Debt Debt-to-Equity Ratio257.04 Current Ratio2.39 Quick Ratio1.61 Sales & Book Value Annual Sales$525.58 million Price / Sales1.59 Cash FlowN/A Price / Cash FlowN/A Book Value$0.16 per share Price / Book106.63Miscellaneous Outstanding Shares48,913,000Free FloatN/AMarket Cap$834.46 million OptionableNot Optionable BetaN/A 10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free Report Key ExecutivesMr. Graeme Neville Duncan (Age 46)CEO & Exec. Director Comp: $1.26MMr. Adeel Ahmad (Age 46)CFO & Exec. Director Comp: $752.73kMr. Karl Ian Belk (Age 52)Chief Operations Officer Comp: $685.79kMr. Robert Sully (Age 47)Gen. Counsel Comp: $669.75kMr. Paul Burden (Age 46)Chief Commercial Officer of Strategic Growth Unit Comp: $638.96kMr. Adam PeelerVP of Investor Relations & CommunicationsMr. Guy Clark (Age 50)Chief Corp. Devel. Officer Mr. Arijit MookerjeeMD and CFO of CPI & CLIMr. Andrew Patrick HoytChief Financial Officer of US Bus.esMr. Robert D. Ford (Age 54)MD & Sr. Director of Legal Affairs of CPI and CLI More ExecutivesKey CompetitorsZentalis PharmaceuticalsNASDAQ:ZNTLDianthus TherapeuticsNASDAQ:DNTHPliant TherapeuticsNASDAQ:PLRXTango TherapeuticsNASDAQ:TNGXArcturus TherapeuticsNASDAQ:ARCTView All Competitors CXRXF Stock Analysis - Frequently Asked Questions How have CXRXF shares performed in 2024? ADVANZ PHARMA's stock was trading at $17.06 at the beginning of 2024. Since then, CXRXF stock has increased by 0.0% and is now trading at $17.06. View the best growth stocks for 2024 here. How do I buy shares of ADVANZ PHARMA? Shares of CXRXF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:CXRXF) was last updated on 5/21/2024 by MarketBeat.com Staff From Our PartnersNext President (Not Trump. Not Biden.)The Freeport SocietyConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial Metals[FREE Ticket] 27 Crypto Experts Reveal Their #1 Picks Crypto 101 MediaClaim Your Complimentary Bitcoin RewardCrypto Swap ProfitsProtect Your Bank Account Before It’s Too LateWeiss Ratings4 Cryptos BETTER than BitcoinTrue Market InsidersBuy this small stock before coming AI Tidal WaveChaikin AnalyticsThis Apple-like Innovator is Revolutionizing HealthcareWall Street Star Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ADVANZ PHARMA Corp. Limited Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.